Executive Team

Jay Z. Zhang, M.S., J.D., Chairman and CEO

Mr. Zhang’s more than 20 years of experience in the U.S. and Chinese biotech industry spans R&D, intellectual property, business development, and legal aspects of the industry.  Mr. Zhang is a registered U.S. patent attorney and is well regarded for his substantial experience and expertise in diagnostic patents.  Mr. Zhang is a professor of intellectual property law at the China Jiliang University Law School, and serves as an editorial board member of the Biotechnology Law Report, a leading U.S.-based biotech law journal.

Previously, Mr. Zhang spent ten years at Myriad Genetics Inc., most recently as Senior Vice President of Intellectual Property.  At Myriad, Mr. Zhang was responsible for company-wide intellectual property strategies, and was involved in R&D, marketing and business development.  He led the successful defense of Myriad’s patents on the BRCA1 and BRCA2 genes in the European Patent Office, declared by the journal Nature as “one of the toughest, and most impenetrable, biological patent cases in the history of the European Patent Office.” (“Europe to Pay Royalties for Cancer Gene,” Nature, 456:556, December 4, 2008).  He also played a leading role in defending Myriad’s U.S. patents on the BRCA1 and BRCA2 genes and diagnostic methods in courts.

Prior to Myriad, Mr. Zhang was a patent attorney at Alston & Bird LLP, and worked in R&D at Merck & Co., Inc.  He was a co-founder of Niiki Pharma Inc., a startup oncology drug development company.  Mr. Zhang graduated with a J.D. from the University of North Carolina School of Law, M.S. in biochemistry and molecular biology from Northwestern University, and B.S. in genetics from Fudan University in China.

Barclay Li, Ph.D., Vice President of Development and Regulatory Affairs

Dr. Li has more than fifteen years of experience in molecular diagnostic R&D. Prior to Shuwen, Dr. Li was a group leader of molecular biology at Sekisui Diagnostics (formerly Genzyme Diagnostics) in the UK. Previously, Dr. Li served as a manager at Thermo Fisher/Life Technologies leading its DNA Manufacturing and Contract Research group in Shanghai. Dr. Li was involved in the development of a number of molecular diagnostic IVD products for Influenza, MRSA, TB, among others, for FDA approval.

Dr. Li received his Ph.D. in molecular biology from the University of Greenwich, UK, M.S. degree in biomedical sciences from the Peking Union Medical College, and B.S. in medicine from Hebei North University in China. He completed his postdoctoral research at the University of Greenwich, UK.

Saaras Hu, Vice President and Clinical Laboratory Director

Mr. Hu has over 20 years of experience in medical diagnosis and clinical reference laboratory management, and has expertise in diagnostic lab quality control and CAP and ISO 15189 certification.  Prior to joining Shuwen, he was the Laboratory Director of Shanghai Clinical Research Center and was responsible for the overall operation of the CAP- and ISO15189-certified diagnostic reference lab of the Center.  Previously, Mr. Hu spent over 10 years at Protech Pharmaservices Corp. (PPC) as Clinical Laboratory Manager, where he worked closely with multinational pharmaceutical companies for laboratory testing of clinical trial samples.  Mr. Hu also worked for more than 10 years as a clinical lab supervisor in Chung Shan Hospital, a 2000-bed teaching hospital affiliated with the Chung Shan Medical College in Taiwan.

Mr. Hu is well published on medical diagnosis and clinical laboratory management.  He is a member of Taiwan Society of Laboratory Medicine and Taipei Society of Medical Technologists.  Mr. Hu received his B.S. in medical technology and M.S. in molecular diagnosis from Chung Shan Medical University in Taiwan.

Vafa Amirkia, Ph.D., Director of Corporate Strategy and Business Development

Dr. Amirkia is responsible for shaping Shuwen’s commercial strategy and forging strategic alliances to drive Shuwen’s sustainable long-term growth globally. Dr. Amirkia holds over 10 years of commercial and regulatory strategy experience specifically focusing on the biotechnology and pharmaceutical industries in China. Prior to Shuwen, Dr. Amirkia drove global, regional, and local business transformation and development initiatives across Asia for LEO Pharma during its fastest period of inorganic investment (totaling >$1bn USD) since the company’s founding in 1908. He also holds consultancy experience with QuintilesIMS (formerly known as IMS Health) as a previous member of its commercial operations team advising a wide range of biotechnology and pharmaceutical clients on growth strategies in emerging markets across the APAC region.

Dr. Amirkia received his Ph.D. in drug development and pharmacology from University College London (UCL) and undergraduate degrees in Animal Physiology and Chinese from the University of Washington. Dr. Amirkia’s research on machine learning in natural product drug discovery, R&D strategy, and commercialization of technologies in the healthcare sector has been published in Frontiers of PharmacologyPhytochemistry Letters, and Bioinformation. Dr. Amirkia has resided in China for 10 years and holds full proficiency in English, Mandarin, and Persian.

Grace Lou, Director of Marketing

Ms. Lou has over 20 years of pharmaceutical and diagnostic sales and marketing experience in China, particularly in oncology and neurology. Previously Ms. Lou held the marketing manager positions at Bayer and AstraZeneca, responsible for national marketing strategies and market launch in various oncology drugs in breast cancer, lung cancer, ovarian cancer and colon cancer. Earlier in her career, Ms. Lou held senior product manager and product manager positions at Roche and Bristol Myers Squibb, and sales representatives with Glaxo Smithkline. Ms. Lou graduated from East China University of Science and Technology majoring in medicinal chemistry.

Chengjun Li, Director of Consumer Testing

Mr. Li is responsible for the marketing and sales of Shuwen’s preventive testing products and services including direct-to-consumer genetic testing in the consumer market outside of hospitals. Prior to Shuwen, Mr. Li spent more than twenty years in sales and marketing of various consumer products including consumer electronics, OTC medical devices, health foods, and other consumer health products, achieving annual sales of more than 500 million RMB. Mr. Li graduated from Anhui Normal University.

Ada Yuan, M.S. (Med.), Medical Director

Ms. Yuan is responsible for the Medical Department at Shuwen, focusing on IVD pre-clinical and clinical development and providing scientific support to the Marketing and Sales. Prior to Shuwen, Ms. Yuan has over fourteen years of experience in pharmaceutical industry with an expertise in the field of oncology.

Ms. Yuan received her M.S. (Med.) in hematology from Fudan University, B.S. (Med.) in clinical medicine from Shandong University in China.